Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2019 | 03-2019 | 12-2018 | 09-2018 | 06-2018 | |
| Sales | 4,523,421 | 4,458,090 | 3,934,083 | 4,330,872 | 4,387,861 |
| Cost of Goods | 730,259 | 720,210 | 615,220 | 688,740 | 696,755 |
| Gross Profit | 3,793,162 | 3,737,880 | 3,318,865 | 3,642,132 | 3,691,105 |
| Operating Expenses | 1,767,550 | 1,570,915 | 1,946,719 | 1,800,044 | 1,738,000 |
| Operating Income | 2,025,871 | 2,167,176 | 1,372,366 | 1,842,828 | 1,953,860 |
| Interest Expense | 199,093 | 156,766 | 49,824 | 93,132 | 119,275 |
| Other Income | 2,259 | 1,978 | -27,512 | -12,168 | 166,345 |
| Pre-tax Income | 1,829,037 | 2,012,388 | 1,295,030 | 1,737,528 | 2,000,930 |
| Income Tax | 384,030 | 422,659 | 229,485 | 327,756 | 345,016 |
| Net Income Continuous | 1,445,007 | 1,589,729 | 1,065,545 | 1,409,772 | 1,655,914 |
| Net Income | $1,445,007 | $1,589,729 | $1,065,545 | $1,409,772 | $1,655,914 |
| EPS Basic Total Ops | 0.30 | 0.33 | 0.22 | 0.29 | 0.34 |
| EPS Basic Continuous Ops | 0.30 | 0.33 | 0.22 | 0.29 | 0.34 |
| EPS Diluted Total Ops | 0.30 | 0.33 | 0.22 | 0.29 | 0.34 |
| EPS Diluted Continuous Ops | 0.30 | 0.33 | 0.22 | 0.29 | 0.34 |
| EBITDA(a) | $2,191,344 | $2,328,203 | $1,616,349 | $1,958,826 | $2,073,157 |